DePalma Ralph G, Hayes Virginia W, May Patricia E, Cafferata H Treat, Mohammadpour Hamid A, Brigg Laura A, Chow Bruce K, Shamayeva Galina, Zacharski Leo R
Department of Veterans Affairs, Washington, DC 20420, USA.
Vascular. 2006 Jul-Aug;14(4):193-200. doi: 10.2310/6670.2006.00039.
This exploratory substudy of The Iron (Fe) and Atherosclerosis Study (FeAST) compared baseline inflammatory markers, including cytokines, C-reactive protein (CRP), and ferritin, in subjects with peripheral arterial disease (PAD) taking statins with subjects with PAD who were not taking statins. Inflammatory markers in the serum of 47 subjects with PAD not taking statins and a healthy cohort of 21 medication-free men were compared with 53 PAD subjects taking statins at entry to the FeAST. Healthy subjects demonstrated lower levels of tumor necrosis factor (TNF)-R1, interleukin-6 (IL-6), and CRP. TNF-alpha R1 averaged 2.28 ng/mL versus 3.52 ng/mL, p = .0025; IL-6 averaged 4.24 pg/mL versus 16.61 pg/mL, p = .0008; and CRP averaged 0.58 mg/dL versus 0.92 mg/dL, p = .0192. A higher level of IL-6 was observed in PAD statin takers versus PAD subjects not taking statins: 19.47 pg/mL versus 13.24 pg/mL, p = .0455. As expected, total cholesterol and low-density lipoprotein levels were lower in the statin-treated group, p = .0006 and p = .0001, respectively. No significant differences in inflammatory cytokines were detected for varying doses of simvastatin. Additionally, no significant differences in inflammatory biomedical markers were found in subjects with PAD alone compared with those with concomitant coronary artery disease (CAD). Unexpectedly, serum inflammatory cytokine IL-6 levels were significantly higher in PAD subjects receiving statins. There was no difference in measured inflammatory markers in PAD subjects with concomitant CAD.
铁（Fe）与动脉粥样硬化研究（FeAST）的这项探索性子研究，比较了服用他汀类药物的外周动脉疾病（PAD）患者与未服用他汀类药物的PAD患者的基线炎症标志物，包括细胞因子、C反应蛋白（CRP）和铁蛋白。将47名未服用他汀类药物的PAD患者血清中的炎症标志物，与21名未服用药物的健康男性组成的队列进行比较，并与FeAST研究入组时的53名服用他汀类药物的PAD患者进行比较。健康受试者的肿瘤坏死因子（TNF）-R1、白细胞介素-6（IL-6）和CRP水平较低。TNF-α R1平均为2.28 ng/mL，而另一组为3.52 ng/mL，p = 0.0025；IL-6平均为4.24 pg/mL，而另一组为16.61 pg/mL，p = 0.0008；CRP平均为0.58 mg/dL，而另一组为0.92 mg/dL，p = 0.0192。与未服用他汀类药物的PAD患者相比，服用他汀类药物的PAD患者的IL-6水平更高：19.47 pg/mL对13.24 pg/mL，p = 0.0455。正如预期的那样，他汀类药物治疗组的总胆固醇和低密度脂蛋白水平较低，p分别为0.0006和0.0001。不同剂量辛伐他汀的炎症细胞因子未检测到显著差异。此外，单独患有PAD的受试者与合并冠状动脉疾病（CAD）的受试者相比，炎症生物标志物没有显著差异。出乎意料的是，接受他汀类药物治疗的PAD患者血清炎症细胞因子IL-6水平显著更高。合并CAD的PAD患者的测量炎症标志物没有差异。
